Clinical trial NCT05280405: Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study
Official title: Impact of Early Proactive Therapeutic Drug Monitoring on the Durability and Efficacy of Infliximab Therapy in Pediatric Inflammatory Bowel Disease: a Multicenter Open-label Randomized-control Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Inflammatory Bowel Diseases
Keywords: Infliximab
Proactive drug monitoring
Lead sponsor: IRCCS Burlo Garofolo
Sponsor class: OTHER
First posted: 2022-03-15
Enrollment: 86
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to assess whether a proactive therapeutic drug monitoring strategy, introduced early during treatment, improves Infliximab (IFX) durability, efficacy and safety in children and young adults with inflammatory bowel disease. Patients with an indication to receive IFX, based on current clinical practice recommendations, will receive the drug either based on IFX concentrations determined before every IFX infusion, starting from the third infusion, or at standard dosing. Approximately 90 patients will be included in this research study. Patients enrolled will be in the study for approximately 12 months.

Detailed description: Inflammatory Bowel Disease (IBD) are relapsing disorders with progressive bowel damage leading to long-term disability.

Infliximab (IFX), is a highly effective and commonly used biologic in IBD. However, up to 40% of patients do not respond to treatment or lose response over time. Low-serum IFX concentrations and the development of antibodies to IFX (ATI) are two major factors affecting IFX efficacy, durability and safety. Standard IFX dose is administered as an IV (in the vein) infusion at 5 mg/kg in a 0, 2, and 6 weeks induction regimen followed by a maintenance regimen with infusions every 8 weeks. This standard dosing is extrapolated from adult studies. IFX has a highly variable pharmacokinetic and pharmacodynamics that is dependent on body weight, disease extent, levels of inflammation and the presence of ATI. In children and young adults with IBD all these factors often result in low-serum IFX concentrations.

Proactive therapeutic drug monitoring, consists in the measurement of drug concentrations on patient's blood, in order to adjust the following administrations (dosing or interval) and maintain a desired concentration of the medication in the body.

This study seeks to determine whether a proactive therapeutic drug monitoring strategy can improve IFX durability, efficacy and safety in children and young adults with IBD. The study will involve approximately 90 patients, aged 6 to 17 years, with IBD. All the patients enrolled in the study will receive IFX at 5mg/kg at week 0, 2 and 6. At week 6 patients will be randomly assigned to receive IFX treatment either based on IFX concentrations determined before every IFX infusion (intervention group) or at standard dosing (control group). Patients will participate in the study for 54 weeks (approximately 12 months) or until IFX discontinuation. During the study, patients will visit the study center at the time of every IFX infusion or in case of disease flares.

Eligibility criteria: Inclusion Criteria:

1. Anti-TNF naïve children and adolescents, 6-17 years, with a diagnosis of IBD confirmed by a prior endoscopic biopsy that is consistent with the diagnosis
2. Indication to start anti-TNF therapy in accordance with current pediatric guidelines for the treatment of pediatric IBD
3. Active inflammation supported by CRP \> 5mg/L and /or FC \> 150 μg/g before the 1st IFX dose

Exclusion Criteria:

1. Consent withdrawal,
2. Stenosing or penetrating disease requiring surgery, abdominal abscess, symptomatic stricture,
3. Abdominal surgery within the previous 6 months,
4. Acute severe ulcerative colitis attack defined by a PUCAI score Ñ 65,
5. Infective contraindication to IFX treatment including positive tuberculin skin test or Quantiferon-TB test, recent opportunistic infection, infection with hepatitis B (HBV), C (HCV), human immunodeficiency virus (HIV),
6. Previous exposure to anti-TNF;
7. Exposure to concomitant prohibited medications including other biologics (including but not limited to ustekinumab, vedolizumab, abatacept, anakinra..), thalidomide, investigational drugs
8. Pregnancy or lactation

Primary outcomes:
measure: Frequency of IFX discontinuation or need for treatment intensification due to non-response or LOR during the first year of treatment.
timeFrame: 54 weeks
Secondary outcomes:
measure: Cumulative probability of IFX discontinuation
timeFrame: 54 weeks
measure: Cumulative probability of Loss of Response
timeFrame: 54 weeks
measure: Frequency of subtherapeutic IFX concentrations
timeFrame: 54 weeks
measure: Frequency of Anti-Infliximab Antibodies
timeFrame: 54 weeks
measure: Frequency of infusion reactions
timeFrame: 54 weeks
measure: Frequency of endoscopic remission
timeFrame: 54 weeks
measure: Frequency of patients with treatment response at the end of induction between 12 and 14 weeks
timeFrame: Week 14
measure: Frequency of patients with clinical remission at 14 weeks
timeFrame: Week 14
measure: Frequency of clinical and biochemical remission at week 14
timeFrame: Week 14
Other outcomes:
Locations:
city: Trieste
country: Italy
facility: Institute for Maternal and Child Health - IRCCS "Burlo Garofolo"
Study officials:
References: